409 related articles for article (PubMed ID: 36110223)
1. Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma.
Peng Y; Wu G; Qiu X; Luo Y; Zou Y; Wei X; Li A
Front Genet; 2022; 13():916024. PubMed ID: 36110223
[No Abstract] [Full Text] [Related]
2. Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma.
Wang W; Ye Y; Zhang X; Ye X; Liu C; Bao L
Front Mol Biosci; 2022; 9():937979. PubMed ID: 35911976
[No Abstract] [Full Text] [Related]
3. Integrating bulk and single-cell RNA sequencing data to establish necroptosis-related lncRNA risk model and analyze the immune microenvironment in hepatocellular carcinoma.
Zhang R; Li Q; Yu X; Hou Y; Yan L; Gao Y; Ji L; Zhang X; Fang M; Huang L; Yu Z; Gao Y; Li M
Heliyon; 2023 Nov; 9(11):e22083. PubMed ID: 38034714
[TBL] [Abstract][Full Text] [Related]
4. Identification and Validation of Necroptosis-Related LncRNA Signature in Hepatocellular Carcinoma for Prognosis Estimation and Microenvironment Status.
Chen C; Wu Y; Chen K; Xia Z; Liu X; Zhang C; Zhao H; Shen A
Front Genet; 2022; 13():898507. PubMed ID: 35754846
[No Abstract] [Full Text] [Related]
5. Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients With Hepatocellular Carcinoma.
Zhou P; Lu Y; Zhang Y; Wang L
Front Oncol; 2021; 11():661758. PubMed ID: 34277410
[TBL] [Abstract][Full Text] [Related]
6. The necroptosis-related signature and tumor microenvironment immune characteristics associated with clinical prognosis and drug sensitivity analysis in stomach adenocarcinoma.
Yang B; Wang Y; Liu T; Zhang M; Luo T
Aging (Albany NY); 2024 Mar; 16(7):6098-6117. PubMed ID: 38546403
[TBL] [Abstract][Full Text] [Related]
7. A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer.
Du X; Pu X; Wang X; Zhang Y; Jiang T; Ge Y; Zhu H
Front Genet; 2022; 13():938250. PubMed ID: 36561319
[No Abstract] [Full Text] [Related]
8. Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma.
Zhu J; Zhao W; Yang J; Liu C; Wang Y; Zhao H
Anticancer Drugs; 2024 Jun; 35(5):466-480. PubMed ID: 38507233
[TBL] [Abstract][Full Text] [Related]
9. Identification of Prognostic Glycolysis-Related lncRNA Signature in Tumor Immune Microenvironment of Hepatocellular Carcinoma.
Bai Y; Lin H; Chen J; Wu Y; Yu S
Front Mol Biosci; 2021; 8():645084. PubMed ID: 33968985
[No Abstract] [Full Text] [Related]
10. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
11. Machine learning-based signature of necrosis-associated lncRNAs for prognostic and immunotherapy response prediction in cutaneous melanoma and tumor immune landscape characterization.
Cui Z; Liang Z; Song B; Zhu Y; Chen G; Gu Y; Liang B; Ma J; Song B
Front Endocrinol (Lausanne); 2023; 14():1180732. PubMed ID: 37229449
[TBL] [Abstract][Full Text] [Related]
12. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
[TBL] [Abstract][Full Text] [Related]
13. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a novel signature to predict prognosis and immune characteristics of pancreatic cancer based on necroptosis-related long non-coding RNA.
Xiong Y; Kong X; Fang K; Sun G; Tu S; Wei Y; Ouyang Y; Wan R; Xiao W
Mol Biol Rep; 2023 Sep; 50(9):7405-7419. PubMed ID: 37452900
[TBL] [Abstract][Full Text] [Related]
15. A novel necroptosis-related lncRNA signature for predicting prognosis and immune response of colon cancer.
Luo J; Peng J; Xiao W; Huang S; Cao Y; Wang T; Wang X
Front Genet; 2022; 13():984696. PubMed ID: 36092933
[No Abstract] [Full Text] [Related]
16. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
17. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and Prognostic Value of Necroptosis-Associated lncRNA Model in Patients with Kidney Renal Clear Cell Carcinoma.
Gu J; He Z; Huang Y; Luan T; Chen Z; Wang J; Ding M
Dis Markers; 2022; 2022():5204831. PubMed ID: 35664432
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of necroptosis-related long noncoding RNA to predict prognosis, immune status, and immunotherapeutic response in clear cell renal cell carcinoma.
Tang H; Chen H; Yuan H; Jin X; Chen G
Transl Cancer Res; 2022 Dec; 11(12):4254-4271. PubMed ID: 36644185
[TBL] [Abstract][Full Text] [Related]
20. A cuproptosis-related lncRNA signature for predicting prognosis and immune response in hepatocellular carcinoma.
Wu J; Yao J; Jia S; Yao X; Shao J; Cao W; Ma S; Yao X; Li H
Heliyon; 2023 Sep; 9(9):e19352. PubMed ID: 37810122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
